Navigation Links
China Biologic Products Announces Approval for Setting Up a New Plasma Collection Station in Pu Bei County, Guangxi Province

TAIAN CITY, Shandong, China, June 30 /Xinhua-PRNewswire-FirstCall/ -- China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("CBP," or "the Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), today announced that the Company received the approval from the Guangxi Province Bureau of Health, to set up a new plasma collection station in Pu Bei County, Guangxi Province.

The new plasma collection station will be located in the Centralized Industry Zone of Pu Bei County and when it becomes operational, it will replace CBP's existing Fang Cheng Plasma Collection Station ("Fang Cheng"). The Company's management decided to relocate the Fang Cheng Plasma Collection Station to a more strategic location to increase collection volumes. During the construction period, the existing Fang Cheng Plasma Station will still continue with its normal operations. With the approval of the new location, the Company hopes to expand its coverage area to secure higher collection volumes in the future.

"Since we received approval to relocate Fang Cheng earlier this year, we inspected several relocation sites and settled on Pu Bei County as the best choice," said Mr. Chao Ming Zhao, the Company's CEO. "We are confident that the new plasma collection station will help to greatly expand our plasma supply once it is established."

About China Biologic Products, Inc.

Through its indirect majority-owned subsidiary Shandong Taibang Biological Products Co. Ltd., China Biologic Products, Inc. (the "Company"), is principally engaged in the research, development, production and manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. The Company's human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases.

Safe Harbor Statement

This release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiary companies. All statements, other than statements of historical fact included herein are "forward-looking statements," including statements regarding: the effect of relocating its plasma collection station, the ability of the Company to achieve its commercial objectives; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

For more information, please contact:

Company Contact:

Mr. Y. Tristan Kuo


China Biologic Products, Inc.

Tel: +86-538- 6202206



Investor Relations Contact:

Mr. Crocker Coulson


CCG Investor Relations

Tel: +1-646-213-1915 (NY office)



SOURCE China Biologic Products, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Clean Energy Updates Business Outlook
2. China-Biotics, Inc. to Supply Probiotics to Pharmaceutical Company
3. Kiwa Bio-Tech Receives Authorization From the Ministry of Commerce of the Peoples Republic of China to Wholesale Other Fertilizer Manufacturers Products
4. Covance and WuXi PharmaTech to Form a Joint Venture to Provide World-Class Preclinical Services in China
5. Beike Biotech Opens Comprehensive Stem Cell Storage and Processing Facility in China
6. PacificGMP to Merge With Pacific Biopharma Group and Create Innovative US-Compliant cGMP Contract Biomanufacturing Facility in China
7. Immtech Pharmaceuticals and Beijing Capital Medical University Announce Joint Venture to Provide Contract Research Services in China
8. ProMetic announces Octapharma publication of PRDTS prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China
9. China Sun Group High-Tech Co. Completes Share Exchange to Create 100% Ownership in DLX Subsidiary
10. Access Licenses ProLindac(TM) to Jiangsu Aosaikang Pharmaceutical Co., LTD., a Leading Oncology Pharmaceutical Company for Manufacturing, Development and Commercialization in the Greater China Region
11. China Kangtai Cactus Biotech Announces Improved Milk Production in Cows From Companys Cactus Cattle Feed
Post Your Comments:
(Date:10/12/2017)... ... October 12, 2017 , ... ... genomics analysis platform specifically designed for life science researchers to analyze and ... researcher Rosalind Franklin, who made a major contribution to the discovery of ...
(Date:10/11/2017)... ... , ... ComplianceOnline’s Medical Device Summit is back for its 4th year. The ... Francisco, CA. The Summit brings together current and former FDA office bearers, regulators, industry ... officials from around the world to address key issues in device compliance, quality and ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the main ... people each year. Especially those living in larger cities are affected by air pollution ... of the most pollution-affected countries globally - decided to take action. , “I knew ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... (ADC) therapeutics, today confirmed licensing rights that give it exclusive global access ... developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, an ...
Breaking Biology Technology:
(Date:8/15/2017)...   ivWatch LLC , a medical device company focused on ... receipt of its ISO 13485 Certification, the global standard for medical ... Standardization (ISO®). ... Continuous Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as ...
(Date:6/23/2017)... N.Y. , June 23, 2017  IBM (NYSE: ... dairy research, today announced a new collaboration using next-generation ... chances that the global milk supply is impacted by ... Cornell University has become the newest academic institution to ... a food safety initiative that includes IBM Research, Mars, ...
(Date:5/16/2017)... N.J. , May 16, 2017  Veratad Technologies, ... provider of online age and identity verification solutions, announced ... K(NO)W Identity Conference 2017, May 15 thru May 17, ... Regan Building and International Trade Center. ... the globe and in today,s quickly evolving digital world, ...
Breaking Biology News(10 mins):